Abstract
Contrast induced nephropathy (CIN) is an iatrogenic form of acute kidney injury (AKI) with variable but growing prevalence secondary to increased need for contrast administration during medical investigations such as coronary angiography. The mechanism of CIN is complex and poorly understood but is believed to be secondary to renal medullary hypoxia secondary to direct tubular toxicity from the contrast media and vasoconstriction. N-acetylcysteine (NAC) an antioxidant and vasodilator, has shown promising results in early investigations but failed to demonstrate consistent results in subsequent clinical trials and their meta-analysis. In this review we aim to discuss pharmacological properties of NAC and appraise the literature regarding the use of NAC for the prevention of CIN after coronary angiography.
Keywords: Acetylcysteine/therapeutic use, angiography/adverse effects, contrast media/adverse effects, humans, kidney diseases/chemically induced, kidney diseases/prevention & control.
Current Drug Therapy
Title:Use of N-acetyl-cysteine to Prevent Nephrotoxicity Associated with Iodinated Contrast Agents
Volume: 9 Issue: 2
Author(s): Mayank K. Mittal, Kanupriya Jain, Harsh Agrawal, Poonam Velagapudi, Sonal Dhuper and Arun Kumar
Affiliation:
Keywords: Acetylcysteine/therapeutic use, angiography/adverse effects, contrast media/adverse effects, humans, kidney diseases/chemically induced, kidney diseases/prevention & control.
Abstract: Contrast induced nephropathy (CIN) is an iatrogenic form of acute kidney injury (AKI) with variable but growing prevalence secondary to increased need for contrast administration during medical investigations such as coronary angiography. The mechanism of CIN is complex and poorly understood but is believed to be secondary to renal medullary hypoxia secondary to direct tubular toxicity from the contrast media and vasoconstriction. N-acetylcysteine (NAC) an antioxidant and vasodilator, has shown promising results in early investigations but failed to demonstrate consistent results in subsequent clinical trials and their meta-analysis. In this review we aim to discuss pharmacological properties of NAC and appraise the literature regarding the use of NAC for the prevention of CIN after coronary angiography.
Export Options
About this article
Cite this article as:
K. Mittal Mayank, Jain Kanupriya, Agrawal Harsh, Velagapudi Poonam, Dhuper Sonal and Kumar Arun, Use of N-acetyl-cysteine to Prevent Nephrotoxicity Associated with Iodinated Contrast Agents, Current Drug Therapy 2014; 9 (2) . https://dx.doi.org/10.2174/1574885509666140716171925
DOI https://dx.doi.org/10.2174/1574885509666140716171925 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of Decoy Oligonucleotides as Novel Therapeutic Strategy: A Contemporary Overview
Current Drug Discovery Technologies From Dual Peroxisome Proliferator Activated Receptor Agonists to Selective Peroxisome Proliferator Activated Receptor Modulators
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Sphingolipids in Genetic and Acquired Forms of Chronic Kidney Diseases
Current Medicinal Chemistry Extracellular Vesicles Isolated from Mesenchymal Stromal Cells Primed with Hypoxia: Novel Strategy in Regenerative Medicine
Current Stem Cell Research & Therapy Patent Selections
Recent Patents on Cardiovascular Drug Discovery Growth and Differentiation of Human Embryonic Stem Cells for Cardiac Cell Replacement Therapy
Current Stem Cell Research & Therapy Effect of miR-128 in DNA Damage of HL-60 Acute Myeloid Leukemia Cells
Current Pharmaceutical Biotechnology Stem Cells: Clinical Trials Results The End of the Beginning or the Beginning of the End?
Cardiovascular & Hematological Disorders-Drug Targets An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery A Review on Electrocardiographic Changes in Diabetic Patients
Current Diabetes Reviews Postoperative Delirium
Current Drug Targets Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design Microcirculation and Heart Failure
Current Pharmaceutical Design Calcium Handling and Arrhythmogenesis
Medicinal Chemistry Neurodegeneration in Niemann-Pick Type C Disease and Huntingtons Disease: Impact of Defects in Membrane Trafficking
Current Drug Targets Antiviral Therapy Targeting Viral Polymerase
Current Pharmaceutical Design Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition General or Local Anesthesia for TAVI? A Systematic Review of the Literature and Meta-Analysis
Current Pharmaceutical Design Nitric Oxide Synthase and Cyclooxygenase Pathways: A Complex Interplay in Cellular Signaling
Current Medicinal Chemistry Meet Our Associate Editor
Current Cardiology Reviews